Telesis Bio Analyst Ratings
Telesis Bio Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | — | Keybanc | Downgrades | Overweight → Sector Weight | |
| 08/04/2021 | 2633.81% | Roth Capital | $45 → $38 | Maintains | Neutral |
| 08/03/2021 | 2633.81% | SVB Leerink | $19 → $38 | Maintains | Market Perform |
| 08/03/2021 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 07/26/2021 | 3137.41% | Roth Capital | $28 → $45 | Maintains | Buy |
| 05/10/2021 | 1266.91% | SVB Leerink | $18 → $19 | Maintains | Market Perform |
| 03/23/2021 | 1194.96% | SVB Leerink | $21 → $18 | Downgrades | Outperform → Market Perform |
| 03/18/2021 | 1914.39% | Roth Capital | $37 → $28 | Maintains | Buy |
| 03/18/2021 | 1914.39% | HC Wainwright & Co. | $32 → $28 | Maintains | Buy |
| 03/18/2021 | 1410.79% | SVB Leerink | $33 → $21 | Maintains | Outperform |
| 03/18/2021 | 1410.79% | Evercore ISI Group | → $21 | Downgrades | Outperform → In-Line |
| 03/18/2021 | 1338.85% | Truist Securities | → $20 | Downgrades | Buy → Hold |
| 03/01/2021 | 2274.1% | SVB Leerink | $34 → $33 | Maintains | Outperform |
| 11/09/2020 | 2346.04% | SVB Leerink | $30 → $34 | Reiterates | → Outperform |
| 10/05/2020 | 1266.91% | Goldman Sachs | → $19 | Initiates Coverage On | → Buy |
| 08/19/2020 | 2346.04% | Citigroup | $35 → $34 | Maintains | Buy |
| 07/07/2020 | 2202.16% | HC Wainwright & Co. | $18 → $32 | Maintains | Buy |
| 07/06/2020 | — | William Blair | Initiates Coverage On | → Outperform | |
| 06/26/2020 | 2058.27% | SVB Leerink | $21 → $30 | Maintains | Outperform |
| 06/26/2020 | 2777.7% | SunTrust Robinson Humphrey | → $40 | Initiates Coverage On | → Buy |
| 07/22/2019 | 1338.85% | Jefferies | → $20 | Initiates Coverage On | → Buy |
| 06/18/2019 | 1698.56% | Roth Capital | → $25 | Initiates Coverage On | → Buy |
| 12/24/2018 | 1410.79% | HC Wainwright & Co. | → $21 | Initiates Coverage On | → Buy |
| 11/14/2018 | 1698.56% | Leerink Swann | $24 → $25 | Maintains | Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/11/2023 | — | Keybanc | 降级 | 增持 → 行业权重 | |
| 08/04/2021 | 2633.81% | 罗斯资本 | 45 美元 → 38 美元 | 维护 | 中立 |
| 08/03/2021 | 2633.81% | SVB Leerink | 19 美元 → 38 美元 | 维护 | 市场表现 |
| 08/03/2021 | — | 威廉布莱尔 | 降级 | 跑赢大盘 → 市场表现 | |
| 2021 年 7 月 26 日 | 3137.41% | 罗斯资本 | 28 美元 → 45 美元 | 维护 | 购买 |
| 2021 年 10 月 5 日 | 1266.91% | SVB Leerink | 18 美元 → 19 美元 | 维护 | 市场表现 |
| 2021 年 3 月 23 日 | 1194.96% | SVB Leerink | 21 美元 → 18 美元 | 降级 | 跑赢大盘 → 市场表现 |
| 03/18/2021 | 1914.39% | 罗斯资本 | 37 美元 → 28 美元 | 维护 | 购买 |
| 03/18/2021 | 1914.39% | HC Wainwright & Co. | 32 美元 → 28 美元 | 维护 | 购买 |
| 03/18/2021 | 1410.79% | SVB Leerink | 33 美元 → 21 美元 | 维护 | 跑赢大盘 |
| 03/18/2021 | 1410.79% | Evercore ISI 集团 | → 21 美元 | 降级 | 跑赢大盘 → 在线 |
| 03/18/2021 | 1338.85% | 信托证券 | → 20 美元 | 降级 | 买入 → 持有 |
| 2021 年 1 月 3 日 | 2274.1% | SVB Leerink | 34 美元 → 33 美元 | 维护 | 跑赢大盘 |
| 11/09/2020 | 2346.04% | SVB Leerink | 30 美元 → 34 美元 | 重申 | → 跑赢大盘 |
| 2020 年 5 月 10 日 | 1266.91% | 高盛 | → 19 美元 | 启动覆盖开启 | → 购买 |
| 2020 年 8 月 19 日 | 2346.04% | 花旗集团 | 35 美元 → 34 美元 | 维护 | 购买 |
| 2020 年 7 月 7 日 | 2202.16% | HC Wainwright & Co. | 18 美元 → 32 美元 | 维护 | 购买 |
| 2020 年 6 月 7 日 | — | 威廉布莱尔 | 启动覆盖开启 | → 跑赢大盘 | |
| 2020 年 6 月 26 日 | 2058.27% | SVB Leerink | 21 美元 → 30 美元 | 维护 | 跑赢大盘 |
| 2020 年 6 月 26 日 | 2777.7% | SunTrust 罗宾逊汉弗莱 | → 40 美元 | 启动覆盖开启 | → 购买 |
| 07/22/2019 | 1338.85% | 杰富瑞 | → 20 美元 | 启动覆盖开启 | → 购买 |
| 06/18/2019 | 1698.56% | 罗斯资本 | → 25 美元 | 启动覆盖开启 | → 购买 |
| 12/24/2018 | 1410.79% | HC Wainwright & Co. | → 21 美元 | 启动覆盖开启 | → 购买 |
| 11/14/2018 | 1698.56% | Leerink Swann | 24 美元 → 25 美元 | 维护 | 跑赢大盘 |
What is the target price for Telesis Bio (TBIO)?
Telesis Bio（TBIO）的目标价格是多少？
The latest price target for Telesis Bio (NASDAQ: TBIO) was reported by Keybanc on August 11, 2023. The analyst firm set a price target for $0.00 expecting TBIO to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.
Keybanc于2023年8月11日公布了Telesis Bio（纳斯达克股票代码：TBIO）的最新目标股价。这家分析公司将目标股价定为0.00美元，预计TBIO将在12个月内跌至-100.00％（可能下跌-100.00％）。去年有1家分析公司公布了评级。
What is the most recent analyst rating for Telesis Bio (TBIO)?
分析师对Telesis Bio（TBIO）的最新评级是多少？
The latest analyst rating for Telesis Bio (NASDAQ: TBIO) was provided by Keybanc, and Telesis Bio downgraded their sector weight rating.
Telesis Bio（纳斯达克股票代码：TBIO）的最新分析师评级由Keybanc提供，Telesis Bio下调了其行业权重评级。
When is the next analyst rating going to be posted or updated for Telesis Bio (TBIO)?
Telesis Bio（TBIO）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Telesis Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Telesis Bio was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
分析师在进行了广泛的研究（包括浏览公开财务报表、与Telesis Bio的高管和客户交谈以及听取财报电话会议）后得出了股票评级。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Telesis Bio的最后一次评级是在2023年8月11日提交的，因此你应该预计下一个评级将在2024年8月11日左右公布。
Is the Analyst Rating Telesis Bio (TBIO) correct?
分析师对 Telesis Bio (TBIO) 的评级正确吗？
While ratings are subjective and will change, the latest Telesis Bio (TBIO) rating was a downgraded with a price target of $0.00 to $0.00. The current price Telesis Bio (TBIO) is trading at is $1.39, which is out of the analyst's predicted range.
虽然收视率是主观的，会发生变化，但最新的Telesis Bio（TBIO）评级被下调，目标股价为0.00美元至0.00美元。Telesis Bio（TBIO）目前的交易价格为1.39美元，超出了分析师的预测区间。